SCHEMBL1623362

SCHEMBL1623362

Cc1cc(Nc2cc[nH]n2)nc(Cl)c1C#N

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.45
AURKA O14965 16/20 0.41
CYP3A4 P08684 8/20 0.41
CYP2D6 P10635 7/20 0.41
CYP1A2 P05177 5/20 0.41
CYP2C9 P11712 4/20 0.38
CYP2C19 P33261 4/20 0.38
RAB29 O14966 1/20 0.38
FYN P06241 1/20 0.38
YES1 P07947 1/20 0.38
LYN P07948 1/20 0.38
FGFR1 P11362 1/20 0.38
SRC P12931 1/20 0.38
KDR P35968 1/20 0.38
AURKB Q96GD4 1/20 0.38
KDM4E B2RXH2 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1623742 0.80 AURKA (0.61) AURKACYP3A4CYP2D6CYP1A2CYP2C9
SCHEMBL31384576 0.76 L3MBTL1 (0.58) L3MBTL1CYP2D6CYP1A2KDM4ETSHR
SCHEMBL31384573 0.76 L3MBTL1 (0.58) L3MBTL1CYP2D6CYP1A2KDM4ETSHR
SCHEMBL9955728 0.76 L3MBTL1 (0.58) L3MBTL1CYP2D6CYP1A2KDM4ETSHR
SCHEMBL12720740 0.76
SCHEMBL1623919 0.75 AURKA (0.46) L3MBTL1AURKACYP3A4CYP2D6CYP1A2
SCHEMBL1622443 0.75 AURKA (0.51) AURKACYP3A4CYP2D6CYP1A2CYP2C9
SCHEMBL1623211 0.75 AURKA (0.46) L3MBTL1AURKACYP3A4CYP2D6CYP1A2
SCHEMBL1621945 0.75 AURKA (0.46) AURKACYP3A4CYP2D6CYP1A2CYP2C9
SCHEMBL23758044 0.75 L3MBTL1 (0.51) L3MBTL1CYP1A2CYP2C9CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1876178-B1 CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2015-05-27 EP claimed
US-20090292121-A1 Cyanopyridine derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-11-26 US claimed
EP-1876178-A1 CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2008-01-09 EP claimed
EP-1876178-B1 CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2015-05-27 EP disclosed
EP-1876178-B1 CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2015-05-27 EP disclosed
US-7928126-B2 Cyanopyridine derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-04-19 US disclosed
US-7928126-B2 Cyanopyridine derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-04-19 US disclosed
US-20090292121-A1 Cyanopyridine derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-11-26 US disclosed
US-20090292121-A1 Cyanopyridine derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-11-26 US disclosed
EP-1876178-A1 CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2008-01-09 EP disclosed
EP-1876178-A1 CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2008-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292121-A1 Cyanopyridine derivative and use thereof as medicine DPYD, IDH1, TP53 L3MBTL1 2078/4885AURKA 172/4885CYP3A4 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.